Agency / Source: Zinc Ahead Ltd | Veeva Systems

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients - Partnership drives commercial excellence through precision engagement to benefit patients in need of options [Nasdaq: ANIP] - ANIPharmaceuticals.com / Cortrophin.com
ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

 

PRZOOM - /newswire/ - Baudette, MN, United States, 2022/06/21 - Partnership drives commercial excellence through precision engagement to benefit patients in need of options [Nasdaq: ANIP] - ANIPharmaceuticals.com / Cortrophin.com. NYSE: VEEV

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

ANI Pharmaceuticals, Inc. and Veeva Systems today announced a collaboration to define and operationalize data-driven commercial strategies for ANI’s new Rare Disease Business Unit. ANI is using software, data, and services from Veeva to establish the digital foundation for the launch of the business unit’s first commercially available product in the U.S.

“To serve rare disease patients with high unmet medical needs, we need to be agile, data-driven, and efficient,” said Christopher Mutz, head of rare disease at ANI. “With Veeva as our trusted partner, we accelerated launch readiness and equipped new sales, medical, and marketing teams with the digital tools they need all with the speed and precision warranted by such an important milestone.”

ANI recently announced the U.S. commercial availability of Purified Cortrophin® Gel (Repository Corticotropin Injection USP) 80 U/mL (cortrophin.com). To prepare for this launch, ANI adopted the complete suite of Veeva Commercial Cloud solutions across its business, including software for multichannel engagement and content management, along with longitudinal patient data for customer segmentation.

“ANI now has a digital foundation that supports its patient-centric approach to commercialization,” said Paul Shawah, executive vice president of commercial strategy at Veeva. “The company is advancing its mission by leveraging data to uncover key patient groups as well as the providers who care for them and empowering its field teams to create meaningful connections.”

Veeva Business Consulting also helps the company use advanced analytics to continuously optimize for the most precise and impactful sales and medical interactions. This allows ANI’s field force to identify new healthcare professionals, while delivering actionable insights so they can best engage with them. Learn more about how ANI launched at speed and scale in an upcoming fireside chat webinar on July 19.

About Veeva Systems

Veeva (veeva.com) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals (anipharmaceuticals.com) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit anipharmaceuticals.com.

ANI Forward-Looking Statements
To the extent any statements made in this release relate to information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words, and the use of future dates. These forward-looking statements include, but are not limited to, statements related to the commercial launch of Cortrophin Gel. Risks and uncertainties that may cause ANI’s actual results to be materially different than those expressed in or implied by such forward-looking statements include, but are not limited to, the costs involved in commercializing Cortrophin Gel, general business and economic conditions, increased competition and strategies employed by competitors, uncertainties regarding the COVID-19 pandemic, market trends for our products, regulatory environment and changes, and other risks and uncertainties that are described in ANI’s Annual Report on Form 10-K, quarterly reports on Form 10-Q, and other periodic reports filed with the U.S. Securities and Exchanges Commission.

Any forward-looking statements in this news release speak only as of the date of this news release and are based on ANI’s current beliefs, assumptions, and expectations. Except as required by law, ANI undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2022, which you can find here (a summary of risks which may impact our business can be found on pages 37 and 38), and in our subsequent SEC filings, which you can access at sec.gov.


Contact:

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado[.]veeva.com

ANI Pharmaceuticals Media Contact
Angela Salerno-Robin
dna Communications
212-445-8219
ASalerno-Robin[.]dna-comms.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Zinc Ahead Ltd | Veeva Systems

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease Patients

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Purified Cortrophin® Gel | Veeva Systems, Inc.
Contact: Deivis Mercado - Veeva.com 
925-226-8821 deivis.mercado[.]veeva.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Zinc Ahead Ltd | Veeva Systems securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Zinc Ahead Ltd | Veeva Systems / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Digital Technologies Drive Growth Across the Biomanufacturing Value Chain Finds Frost & Sullivan
DSM Starts Construction of Large Scale Production Facility for its Novel Methane-reducing Feed Additive for Ruminants, Bovaer® in Dalry, Scotland
Collaboration Between Drug and Medical Food Manufacturers to Boost Market Growth Says Frost & Sullivan
Parexel Recognized by Frost & Sullivan with 2022 Global Customer Value Leadership Award
Ipsen’s Global Natural History Study of Fibrodysplasia Ossificans Progressiva Shows Debilitating Impact of the Disease Over An Individual’s Lifetime
BASF and Evonik Partner to Reduce the Environmental Footprint of the Feed and Animal Protein Industries
Rely+On Virkon from LANXESS Effective Against Monkeypox Virus
DSM Completes Acquisition of Prodap
Bruker’s Arxspan Business for Lab Informatics Expands Customer Capabilities by Joining Tetra Partner Network
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-line Monotherapy for Small Cell Lung Cancer

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  Limelon Advertising, Co.







 
  ©2022 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today